🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are escalating around the world, with data suggesting more than 82 million new cases each year. Notably increased rates are observed in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Secure Authorization

One new antibiotic, also known as Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This infection can lead to major issues, including infertility. Scientists hope that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in the same week. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a huge turning point in the management of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Results and Global Access

Based on data released by a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which uses an injection and a pill. The study enrolled over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors treating patients have expressed positive views. The availability of a one-pill regimen like this is described as a "critical tool" for managing the epidemic. This is considered essential to alleviate the strain of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.